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Summary
Broadly neutralizing antibodies to HIV-1 (bNAbs) can prevent infection and are therefore of great
importance for HIV-1 vaccine design. Notably, bNAbs are highly somatically mutated and
generated by a fraction of HIV-1-infected individuals several years after infection. Antibodies
typically accumulate mutations in the complementarity determining region (CDR) loops, which
usually contact the antigen. The CDR loops are scaffolded by canonical framework regions
(FWRs) that are both resistant to and less tolerant of mutations. Here we report that in contrast to
most antibodies, including those with limited HIV-1 neutralizing activity, most bNAbs require
somatic mutations in their FWRs. Structural and functional analyses reveal that somatic mutations
in FWR residues enhance breadth and potency by providing increased flexibility and/or direct
antigen contact. Thus, in bNAbs, FWRs play an essential role beyond scaffolding the CDR loops
and their unusual contribution to potency and breadth should be considered in HIV-1 vaccine
design.
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Introduction
A fraction of HIV-1-infected individuals mount a broadly neutralizing serologic response
(Doria-Rose et al., 2010; Simek et al., 2009) 2–3 years after infection (Mikell et al., 2011).
Antibodies generated by these individuals are of great interest for vaccine design because
they can protect macaques from infection (Mascola et al., 2000; Moldt et al., 2012; Shibata
et al., 1999). Moreover, combinations of broadly neutralizing antibodies can control an
established HIV-1 infection in humanized mice (Klein et al., 2012b).
Despite their potential importance to vaccine development and HIV-1 therapy, little was
known about the molecular composition of the human anti-HIV-1 antibody response until
single cell antibody cloning techniques were developed and used for characterizing IgGs
from the sera of HIV-1-infected individuals with broadly neutralizing activity (Scheid et al.,
2009a; Scheid et al., 2009b). This analysis revealed highly potent bNAbs, all of which might
eventually be used in vaccine development (Corti et al., 2010; Huang et al., 2012; Morris et
al., 2011; Mouquet et al., 2012; Scheid et al., 2011; Walker et al., 2009; Walker et al.,
2011b; Wu et al., 2010.
A surprising observation was that anti-HIV-1 antibodies are highly somatically mutated
when compared to other immunoglobulins (IgGs) cloned from the same patients (Scheid et
al., 2009a; Xiao et al., 2009a; Xiao et al., 2009b). Whereas most human antibodies that have
undergone affinity maturation carry 15–20 somatic mutations (Tiller et al., 2007), potent
broadly neutralizing antibodies carry 40–110 mutations (Corti et al., 2010; Scheid et al.,
2011; Walker et al., 2009; Walker et al., 2011b; Wu et al., 2010; Xiao et al., 2009a; Xiao et
al., 2009b). These mutations are essential because reversion to the antibody germline
sequence drastically reduces neutralizing potency and breadth (Mouquet et al., 2010; Scheid
et al., 2011; Wu et al., 2011; Xiao et al., 2009b; Zhou et al., 2010). However, why so many
mutations appear to be required is not known.
Wu and Kabat first divided antibody variable regions into complementarity determining
regions (CDRs) and framework regions (FWRs) based on the number of somatic
hypermutations in these regions (Wu and Kabat, 1970) (Figure 1A, and B). The CDRs
consist primarily of loops that form the sites of contact between the antibody and antigen
(Amzel and Poljak, 1979), and account for the specificities of most antibody molecules as
demonstrated by CDR grafting experiments (Jones et al., 1986). The structural integrity of
the variable domains is maintained by the FWRs, which encode nine anti-parallel β-strands
arranged into two β-sheets (one sheet containing strands A, B, E and D and the other
containing strands C”, C’, C, F and G; Figure 1A and B). The relatively invariant β-strands
of the FWRs serve as a scaffold for three CDR loops, which connect strands B and C, C’
and C”, and F and G (Figure 1A and B) (Amzel and Poljak, 1979).
Somatic mutations are preferentially found in the CDR loops where they can alter the
antibody combining site without affecting the overall structure of the variable domain (Wu
and Kabat, 1970). Mutations in the FWR are usually poorly tolerated and generally biased to
neutral substitutions to avoid changes that would destroy the structural underpinnings of the
variable domain (Reynaud et al., 1995; Wagner et al 1995).
Here we examine the role of somatic mutations in the development of broadly neutralizing
anti-HIV-1 antibodies. In contrast to most other antibodies, including anti-HIV-1 antibodies
with limited neutralization activity, we found that FWR mutations, including non-contact
residues, are essential for the neutralizing activity of most potent bNAbs. We propose that
the requirement to alter the FWR, without destroying its essential structural elements,
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accounts for the high mutation load found in broadly neutralizing anti-HIV-1 antibodies and
possibly for the difficulty and prolonged latency with which such antibodies develop.
Results
Somatic Hypermutation in HIV-neutralizing Antibodies
To examine the role of somatic hypermutations in anti-HIV-1 antibody neutralization
breadth and potency, we selected a group of 9 HIV-1-reactive antibodies with activity
limited to easy to neutralize (Tier 1) HIV-1 strains (Seaman et al., 2009), and 17 antibodies
with broad neutralization activity (Figure 1C, Figure S1 and Table S1). The antibodies with
limited neutralizing activity included antibodies recognizing the CD4 binding site (CD4bs;
6–187, 9–913, 11–989) (Mouquet et al., 2011; Scheid et al., 2009a), the core epitope (1–479,
2–491, 11–591) (Mouquet et al., 2011; Pietzsch et al., 2010; Scheid et al., 2009a), the V3-
loop (447-52D, 10–188) (Gorny et al., 1993; Mouquet et al., 2011) and the CD4-induced site
(17b) (Thali et al., 1993) (Table S1). Eight of the 17 bNAbs also recognize the CD4bs
(VRC01, NIH45–46, 3BNC60, 12A12, 1NC9, 8ANC131, 12A21, 3BNC117) (Scheid et al.,
2011; Wu et al., 2010), whereas others recognized the V1/V2 loop (PG16) (Walker et al.,
2009), carbohydrates (2G12) (Calarese et al., 2003; Trkola et al., 1996), the core epitope
(HJ16) (Corti et al., 2010), the base of the V3-loop (10–1074, PGT128) (Mouquet et al.,
2012; Walker et al., 2011a), the membrane proximal external region (MPER; 4E10, 2F5)
(Buchacher et al., 1994; Muster et al., 1993) and two antibodies (3BC176 and 8ANC195)
(Klein et al., 2012a; Scheid et al., 2011) for which the precise epitopes are not yet
determined (Figure 1C and Table S1).
Antibodies with limited neutralizing activity differ from bNAbs in that they generally carry
fewer somatic mutations (Figure 1C, Figure S1 and Table S1). We used the well accepted
Kabat system (Wu and Kabat, 1970) that utilizes sequence comparisons for FWR/CDR
assignments. However, direct comparisons between Kabat and the IMGT numbering system
(Giudicelli et al., 2006) (Figure 1B), which includes antibody structural data, were also
performed for a subset of antibodies.
Complete reversion of somatic mutations in the heavy and light chain V genes (FWR1–3
and CDR1/2) drastically reduces anti-HIV-1 antibody binding and neutralization activity
(Buchacher et al., 1994; Mouquet et al., 2010; Scheid et al., 2011; Xiao et al., 2009b; Zhou
et al., 2010). Moreover, reverting only the CDR1 and CDR2 in 3BNC60 and NIH45–46
strongly diminished binding and neutralization (Figure S2A, Supplementary Data 1A). To
determine the functional consequences of FWR mutations, we reverted the framework
residues to their germline counterparts (FWR-GL) in each of the 26 selected antibodies
(Supplementary Data 1B–D) and evaluated binding to HIV-1 envelope proteins as well as
their neutralization activities.
HIV-1-reactive Antibodies with limited Activity
As expected, reversion of somatic mutations in the FWR residues (FWR-GL) of the HIV-1
antibodies with limited breadth had only minimal effects on binding of most of these
antibodies to gpl40YU2 (Figure S2B) as measured by ELISA and confirmed by SPR (not
shown). Only two of these FWR-GL antibodies (9–913 and 10–188) showed a decrease in
binding (Figure S2B). In agreement with the ELISA and SPR experiments, we found little or
no change in neutralizing activity in most of the FWR-GL antibodies with limited
neutralization activity on a panel of up to 6 Tier 1 viruses representing clades A, B and C
(Figure S2B and Table S2). Only antibodies 9–913 and 10–188, which displayed decreased
binding to gpl40YU2, showed a decrease (9–913) or complete loss (10–188) in neutralizing
activity (Figure S2B and Table S2). We conclude that with two exceptions out of 9
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antibodies tested, FWR mutations do not alter the binding or neutralizing activity of anti-
HIV-1 antibodies with limited neutralizing activity. Thus, despite their significantly higher
levels of somatic mutation, HIV-1 neutralizing antibodies with limited breadth resemble
previously characterized antibodies to other antigens in that FWR mutations seem not to be
essential.
Potent Broadly Neutralizing Antibodies
In contrast, reversion of the FWR mutations in most of the 17 broadly neutralizing
antibodies decreased their binding to gpl40YU2 (Figure 2 and Figure 3). Three of the
antibodies, PG16 (Walker et al., 2009), 8ANC195 (Scheid et al., 2011) and 3BC176 (Klein
et al., 2012a) bound poorly to gpl40YU2 when measured up to 8 µg/ml and differences in
binding between mutated and reverted antibodies could not be evaluated (Figure 2).
The neutralizing activity of the reverted antibodies was tested on a panel of 11 viruses (Tier
1 to Tier 3) representing HIV-1 clades A, B and C (Figure 2, Figure 3 and Table S2). The
majority of the FWR-GL antibodies lost nearly all their neutralizing activity against the
tested strains. Similar results were also obtained when we produced FWR-GL antibody
versions of VRC01, 3BNC60 and 8ANC131 according to IMGT alignment (Supplementary
Data 1F, Figure S2C). 4E10, which is among the least potent antibodies of the bNAbs tested,
was the exception to the rule in retaining binding to gpl40YU2 as well as potency and
breadth. PG16 retained most of its neutralizing breadth, but like the other bANbs, it lost
potency by at least 10-fold after FWR reversion (geometric mean IC50 values increased
from 0.95 to 9.69, Figure 2 and Table S2). 2G12 represents a special case for interpreting
the effects of FWR residue reversion because the two Fabs of 2G12 IgG form a domain-
swapped (Fab)2 unit that creates a single antigen binding site for recognizing a constellation
of host-derived high mannose carbohydrates on gp120 (Calarese et al., 2003) (Figure S3).
FWR residues are critical for the Fab dimerization via domain swapping (Huber et al., 2010)
as well as for formation of a novel carbohydrate binding site at the VH-VH’ interface
(Calarese et al., 2003).
To provide a general understanding of the relationship between direct FWR contacts and
CDRH3 length on the degree of FWR somatic mutation, we analyzed these parameters for
bNAbs for which antibody-antigen structures have been determined. No correlation was
observed with CDRH3 length and degree of heavy chain, light chain or total amount of
FWR somatic mutation (Figure S4). Notably, however, the FWR contact surface area with
antigen did correlate with the total number of amino acid changes in FWRs (Figure S4; p-
value = 0.0088; rho=0.533).
To determine whether the effects of FWR reversion on binding and neutralization were
simply due to alterations in contact residues, we selectively reverted all mutated FWR
residues except for the contact residues (FWR-GLCR+; Figure 3) in 4 bNAbs whose contact
residues were known (VRC01, NIH45–46, 12A21, 3BNC117) (Scheid et al., 2011; Wu et
al., 2011; Zhou et al., 2010; Zhou et al., submitted). Despite retaining their FWR contact
residues, all of the partially reverted antibodies showed lower levels of binding by ELISA
and SPR. Interestingly, the SPR binding curves showed that loss of affinity appeared to be
primarily due to an increased dissociation rate (off-rate; kd) (Figure 3). We conclude that
FWR mutations enhance the affinity of broadly neutralizing antibodies primarily by
decreasing the dissociation rate. Most importantly, FWR-GLCR+ antibodies that retained
somatically mutated FWR contact residues lost both neutralizing breadth and potency
(Figure 3 and Table S2). We conclude that FWR mutations in non-contact residues are
essential for the binding, breadth and potency of most broadly neutralizing anti-HIV-1
antibodies.
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Importance of a FWR insertion in 3BNC60
Insertions and deletions are infrequent by-products of somatic hypermutation that occur as a
result of double-strand DNA breaks induced by deamination of neighboring cytidine
residues by activation induced cytidine deaminase (AID) (Pavri and Nussenzweig, 2011;
Wilson et al., 1998). Nevertheless, several potent anti-CD4bs antibodies, including
3BNC60, contain insertions within FWRs that are acquired during somatic mutation (Scheid
et al., 2011). Sequence analysis of the clonal relatives of 3BNC60 (clone RU01) revealed a
correlation between the presence of this insertion and neutralizing activity (Figure 4).
Superimposition of the 3BNC60 Fab structure onto the Fab portion of the NIH45–46/gpl20
complex structure (Diskin et al., 2011) suggested that this insertion might enhance binding
by interacting with the V1/V2 loop region that was truncated in the gpl20 construct that was
crystallized (Figure 5A) (similar results were found when superimposing the 3BNC60 Fab
onto the 3BNC117 Fab, two nearly identical antibodies, in the 3BNC117/gpl20 co-crystal
structure (Zhou et al., submitted)). To assess the effects of the insertion within FWR3 of the
3BNC60 heavy chain, we constructed a 3BNC60 mutant (3BNC60∆I) in which the Trp-
Asp-Phe-Asp insertion was removed (Figure 5B) and evaluated its neutralization activity
against a panel of 7 viruses chosen to include strains that were resistant to VRC01 but
sensitive to 3BNC60 (Figure 5C). 3BNC60AI lost neutralization potency against all 7
viruses. Adding the insertion to 3BNC55, a weaker variant of 3BNC60 isolated from the
same donor (Scheid et al., 2011), increased the neutralization potency of 3BNC55+I
compared to 3BNC55 against one viral strain (TRO.11) (Figure 5C). Addition of the
insertion did not, however, restore the ability of a VRC01 plus insertion mutant to neutralize
VRC01-resistant viruses (Supplementary Data 1E and Table S2). Taken together, these
results demonstrate that the FWR insertion is critical for the neutralization activity of
3BNC60, but that its ability to improve potency requires a precise recognition geometry that
is not always found in other potent anti-CD4bs antibodies.
Crystal structure of a partially-reverted Fab
We previously noted a disruption in the canonical variable domain fold of the VH domain of
3BNC60 (Scheid et al., 2011); namely, the main chain hydrogen bonding pattern between
strands C” and C’ was disrupted by the presence of Pro61 (Kabat numbering position 60;
IMGT position 68) located at the C-terminal end of strand C” (Figure 6A). In contrast, the
germline VH sequence and other potent anti-CD4bs antibodies contain an alanine at this
position (Scheid et al., 2011) (Supplementary Data 1C and D). A proline within a β-strand
cannot form a main chain hydrogen bond with a carbonyl oxygen in an adjacent β-strand
because it lacks a hydrogen atom attached to its mainchain nitrogen (Figure 6A).
Nevertheless, this proline mutation is associated with increased antibody potency among
clonal members of the 3BNC60 family (Figure 4) (Scheid et al., 2011).
Although classified by Kabat (Kabat et al., 1991) as part of CDRH2, residue 61 is within the
C” β-strand of the Ig V domain fold and is classified as a FWR residue by IMGT (Lefranc et
al., 1999) (Figure 1B, Figure S5). Thus we were interested in its potential role in antigen
recognition. In the structure of the free 3BNC60 Fab, the region surrounding Pro61 is
stabilized by a crystal contact (Figure S6) into a position that would clash with the CD4
binding loop of gpl20 (Diskin et al., 2011; Scheid et al., 2011; Wu et al., 2011; Zhou et al.,
2010). The potential clash with gpl20 suggests that the region surrounding 3BNC60 Pro61
rearranges upon gpl20 binding. Indeed, in the structure of a gpl20 complex with the nearly
identical antibody 3BNC117, the Fab exhibits a canonical VH domain structure in its gpl20-
bound conformation (Zhou et al., submitted) (Figure 6A). In addition, a murine Fab structure
including a proline at this position shows minimal disruption of the β-sheet including strand
C” (Stanfield et al., 1990) (Figure 6A).
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To address the unusual properties of the C” strand in 3BNC60, we solved the 2.65 Å crystal
structure of 3BNC60P61A (pdb code 4GW4), a single amino acid revertant mutant form of
3BNC60 (Figure 6A, Table S3). Like other Fabs containing alanine at position 61, including
VRC01 (Zhou et al., 2010), VRC03, VRC-PG04 (Wu et al., 2011) and NIH45–46 (Diskin et
al., 2011; Scheid et al., 2011), strand C” of 3BNC60P61A Fab exhibited normal hydrogen
bonding to the neighboring C’ strand (Figure 6A). Although the displaced region of strand
C” in the 3BNC60 Fab was involved in interactions with a crystallographic neighbor,
perhaps stabilizing it in the conformation observed in the structure (Scheid et al., 2011), the
corresponding region of strand C” in the 3BNC60P61A Fab did not contact a crystallographic
neighbor despite isomorphous packing interactions in the 3BNC60 and 3BNC60P61A
crystals (Figure S6).
To further evaluate the effects of the Pro to Ala substitution in strand C”, we compared the
thermal stability of the 3BNC60 and 3BNC60P61A Fabs (Figure 6B). Both proteins exhibited
denaturation profiles characteristic of two-state (native to denatured) unfolding, however the
3BNC60P61A Fab showed increased thermal stability compared with the wild-type 3BNC60
Fab, as demonstrated by a higher transition midpoint (Tm) (Figure 6B).
The functional consequences of the Pro to Ala substitution were evaluated by comparing the
neutralization potencies of 3BNC60 and 3BNC60P61A IgGs against 19 representative strains
sensitive to 3BNC60 (Figure 6C). The substitution affected the neutralizing activity of the
antibody against 7 of the strains (highlighted red; Figure 6C). We conclude that somatic
mutation in the β-sheet framework involving strand C” is essential for the potency and
breadth of 3BN60.
Discussion
The β-sandwich structure of the immunoglobulin fold lends itself to a natural division into
relatively structurally invariant β-strand FWRs and the more structurally diverse loops
connecting the β-strands, three of which form the hypervariable CDRs (Figure 1A, B). Thus,
mutations in FWRs are usually poorly tolerated and selected against, whereas mutations in
the structurally diverse CDRs are well tolerated. Starting with the first crystal structure of a
Fab bound to a protein antigen (Amit et al., 1986), antibody-antigen complex structures have
confirmed that residues within the CDR loops usually form the majority of contacts with the
antigen. Therefore the primary role of FWR residues is to provide a scaffold for the antigen-
contacting CDRs, as evidenced by the common practice of CDR grafting (Jones et al.,
1986). However, we find that in contrast to most antibodies, including HIV-1-reactive
antibodies with limited neutralizing activity (Figure S1, S2B), somatically mutated FWR
residues are critical for the breadth and potency of broadly neutralizing anti-HIV-1
antibodies (Figure 2 and Figure 3). Thus, the FWRs in these unusual antibodies serve an
essential function beyond that of a scaffold for antigen-binding CDRs.
Understanding the excessive somatic hypermutation found in bNAbs requires consideration
of the process by which antibodies are mutated. B cells undergo somatic hypermutation in
germinal centers during T cell-dependent immune responses (Victora and Nussenzweig,
2011). The mutations are introduced by AID, which preferentially targets cytosines
embedded in RGYW nucleotide sequences (in which R can be A or G, Y can be C or T, and
W can be A or T) in antibody variable regions (Pavri and Nussenzweig, 2011). However,
mutations are not limited to cytidine residues because error prone repair mechanisms also
contribute to the repair of the initial lesions (Pavri and Nussenzweig, 2011; Peled et al.,
2008). Thus, the mutation process is far more random than it would occur if only RGYW
cytidines were targeted.
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Mutations that enhance antibody affinity are rare, but they are positively selected in the
germinal center as a result of increased antigen uptake and MHC-peptide presentation,
which results in increased T cell-mediated help (Victora and Nussenzweig, 2011). Mutations
that increase antibody affinity can do so by increasing the on-rate or by decreasing the off-
rate. The on-rate is diffusion limited, and the off-rate is limited by speed of antigen
internalization because once the antigen is in a degradative endosome it will be digested
irrespective of its rate of release from the antibody (Batista and Neuberger, 1998; Foote and
Milstein, 1991). Thus, naturally developing antibody affinities do not normally exceed an
affinity of 10−11 M. In humans, this degree of affinity maturation is usually achieved with an
average of 10–15 nucleotide mutations focused in the antigen contact residues in the CDR
loops.
Although somatic mutations occur throughout the variable region, mutations that alter the
amino acid coding sequence of the antibody accumulate preferentially in CDRs in part
because of higher level of degeneracy of the codons used in the FWRs (Jolly et al., 1996;
Reynaud et al., 1995; Wagner et al., 1995). Any alterations in the FWR are constrained by
the fact that they must conserve the overall structure of the antibody because B cells that fail
to express surface Ig are destined to die by apoptosis (Rajewsky, 1996). Indeed the FWRs
appear to have evolved a nucleotide coding sequence that resists mutation in order to
prevent changes in relatively invariant β-strands that are required to scaffold the CDR loops
(Jolly et al., 1996; Reynaud et al., 1995; Wagner et al., 1995). Thus, a large number of
random nucleotide mutations would be required to alter the FWR in a manner that optimizes
the broadly neutralizing anti-HIV-1 antibodies while conserving essential structural
elements.
The mutated FWR residues in the broadly neutralizing anti-HIV-1 antibodies contribute to
binding and enhance breadth and potency in several different ways. In some cases, the
substituted FWR residues directly contact the antigen; for example, crystal structures of the
bNAbs VRC01 and NIH45–46 complexed with gpl20 (Diskin et al., 2011; Zhou et al., 2010)
reveal that FWR residue Arg71 in both VRC01 and NIH45–46 forms a salt bridge with
gpl20 residue Asp368. Thus, FWR mutation can serve to directly increase the binding
interface by recruiting portions of the antibody that are not normally involved in antigen
recognition. Moreover the ligand-bound structure of PGT128 (Pejchal et al., 2011) shows
that the carbohydrate attached to Asnl21gp120 interacts with residues within the C” β-strand
of the antibody heavy chain (Trp56, Thr57, His59 and Lys64). Two of these residues
represent somatic mutations. In other cases, FWR residues do not appear to directly contact
the antigen, yet are required for potency. For example, the FWRs of PG16 do not contribute
substantially to direct antigen contacts and interaction with the antigen is mainly mediated
through a long CDR3 loop (Pancera et al., submitted) (Figure S4).
Somatic mutation of residues within the β-sheet framework of the V domain can also
indirectly affect the V domain structure so as to facilitate HIV-1 antigen recognition, as
exemplified by the Pro61 residue in the broadly neutralizing antibodies 3BNC60/3BNC117
(Figure 6). Residue 61 falls within the β-sheet framework of the Ig V domain. Substitution
of this proline to the germline alanine in 3BNC60 resulted in increased thermal stability, but
a loss of neutralization activity against some HIV-1 strains. The structural effects of the
proline to alanine substitution were revealed by comparison of the crystal structures of the
3BNC60P61A and 3BNC60 Fabs: the VH domain β-strand that was disrupted by the proline
in the 3BNC60 structure was restored to its canonical position in the mutant Fab structure
(Figure 6A). In the 3BNC117/gpl20 structure (Zhou et al., submitted), the Pro61-containing
β-strand is shifted from its position in the free 3BNC60 structure (where it was likely
stabilized into the observed conformation by crystal packing forces) in order to avoid
clashing with the CD4-binding loop in gpl20, as predicted previously for 3BNC60/gpl20
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complexes (Scheid et al., 2011) (Figure 6A). The lower thermal stability of 3BNC60 Fab
compared with 3BNC60P61A Fab (Figure 6B) is consistent with flexibility that would allow
this sort of displacement.
Superimposition of the 3BNC60P61A Fab into the 3BNC117/gpl20 co-crystal structure
(Zhou et al., submitted) suggests that an alanine would be accommodated equally as well as
a proline at position 61, and the fact that the P61A mutant of 3BNC60 neutralizes some
HIV-1 strains equally as well as wildtype 3BNC60 suggests that Pro61 does not make any
direct contacts to HIV-1 gpl20 that are critical for binding to gpl20 and neutralization.
Instead we speculate that in the case of 3BNC60 and 3BNC117, the ability to disrupt the C’
– C” portion of the C’C”CFG β-sheet, which provides flexibility for VH residues 60–66, is
necessary in order to accommodate antigenic sequence heterogeneity in or near the gpl20 V5
loop. Taken together, these results provide a counterintuitive example of a neutral or
functionally favorable somatic mutation that decreases the Fab stability by disrupting the
canonical VH domain fold, allowing flexibility of the β-sheet framework that is needed for
optimal antigen binding and neutralization (Figure 6C).
The high level of mutation found in broadly neutralizing antibodies would be difficult to
explain in the context of an immune response to a conventional antigen and a single round
of germinal center selection. However, HIV-1 differs from conventional antigens in that it
presents the host with a continuously evolving target that is selected on the basis of its
ability to evade the antibody response (Wei et al., 2003). We speculate that HIV-1 variants
selected for their ability to evade antibodies due to lowered affinity will recall memory B
cells to the germinal center for additional rounds of mutation and selection. Thus, iterative
rounds of antibody mutation, selection, and viral escape would facilitate the accumulation of
essential mutations in the FWR that conserve some key aspects of antibody structure while
altering others to enhance anti-HIV-1 breadth and potency.
In conclusion our experiments suggest a molecular and a structural rationale for the
requirement of high levels of somatic mutation found in broadly neutralizing antibodies and
possibly for the observation that it takes several years for infected individuals to develop
such antibodies. The high relevance of FWR mutations should be considered in the approach
to designing an HIV-1 vaccine.
Experimental procedures
Sequence analysis of HIV-1-reactive antibodies
Analysis of heavy and light chain gene segment usage, number of somatic mutations, and
the presence of deletions or insertions was carried out using the NCBI IgBLAST software
(http://www.ncbi.nlm.nih.gov/igblast/). Complementarity determining regions (CDRs) and
framework regions (FWRs) were designated according to the Kabat (Wu and Kabat, 1970)
(Figure 1, Supplementary Data 1A–E and Table S1) or IMGT numbering system (Figure 1B
and Supplementary Data 1F) using IgBLAST software. VRC01- and NIH45–46-FWR-
GLCR+ antibodies were designed to carry reverted FWRs with unreverted contact residues
based on the crystal structure of a gpl20-VRC01 complex (Zhou et al., 2010). 3BNC117-
and 12A21-FWR-GLCR+-antibodies were based on the co-crystal structures as described by
Peter Kwong and colleagues (Zhou et al., submitted). Any residue with a buried surface area
(BSA) greater than 5 Å2 was considered significant.
Sequences of the RU01 clone (Scheid et al., 2011) were aligned using Clustal V from the
DNAstar package using PAM 250 matrix. The phylogenetic tree was constructed using the
DNAstar package, which employs a neighbor joining method. Bootstrap values (1000 trials,
seed=111) are as indicated (Figure 4). Classification of neutralization potency (RU01 clone)
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was based on the neutralization activity. Antibodies were grouped into potent, intermediate
and poor neutralizers by taking into account the potency (IC50) against BaL.26, DJ263.8,
6535.3, RHPA4259.7, Tro.11, PV0.4 and YU2.DG as well as breadth (number of the tested
strains neutralized)(Scheid et al., 2011).
Cloning, expression and purification of immunoglobulins
The variable regions of all mature, FWR-GL, FWR-GL GLCR+ and CDR1/2 GL antibodies
were cloned into the same IgH, Igκ or Igλ backbones encoding the constant domains of the
antibodies. Reversions of the FWRs were introduced by overlapping polymerase chain
reaction (PCR) or by DNA synthesis (Integrated DNA Technologies). The sequence of 17b
was obtained from the structure with CD4 (pdb code 1G9M). The P61A mutation was
introduced into the 3BNC60 heavy chain gene by site-directed mutagenesis using
QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies). Since the region of the
FWR3 insertion is highly mutated and the exact location of inserted amino acids is difficult
to determine, surrounding regions from 3BNC55 and 3BNC60 were included in each
construct (Figure 5B). Likewise, the residues surrounding the engrafted insertion in VRC01
were chosen based on the crystal structures of VRC01 and 3BNC60 (Supplementary Data
1E) (Scheid et al., 2011; Zhou et al., 2010). Antibodies were expressed and purified as
previously described (Mouquet et al., 2011) (Diskin et al., 2011).
ELISA
ELISAs for analysing antibody-binding to gp140YU2 (Figure 2,Figure 3 Figure S2) was
performed as previously described (Mouquet et al., 2011).
Neutralization assays
Neutralizing activities of mature, FWR-GL, FWR-GLCR+, and CDR1/2-GL antibodies were
determined using a TZM.bl assay as previously described (Diskin et al., 2011; Li et al.,
2005; Montefiori, 2005; Seaman et al., 2009). Briefly, TZM.bl cells were infected with
different Tier 1 to Tier 3 HIV-1-Env-pseudoviruses in the presence of serial dilutions of the
antibodies tested. Antibodies with neutralizing activity inhibit the infection and a reduction
of luciferase reporter gene expression can be measured 48h after infection. IC50 values were
calculated based on the antibody concentration that resulted in a 50% reduction of relative
luminescence units (RLU).
Surface plasmon resonance
Experiments were performed with a Biacore T200 (Biacore, Inc) as described previously
(Diskin et al., 2011). Briefly, YU-2 gpl40 was primary amine-coupled on CM5 chips
(Biacore, Inc.) at an immobilization level of 1000 RUs. IgG antibodies were injected over
flow cells at 1 µM, at flow rates of 90 µl/min. The sensor surface was regenerated by a 50
sec-injection of 10 mM glycine-HCl pH 2.5 at a flow rate of 90 µ1/min.
Crystallization and structure of 3BNC60P61A Fab
3BNC60P61A Fab (pdb code 4GW4) was concentrated to 13.7 mg/ml in 20 mM Tris pH 8.0,
150 mM sodium chloride, 0.02% sodium azide (TBS) buffer. Crystals of Fab 3BNC60P61A
were obtained by mixing a protein solution at 13.7 mg/ml with 16% polyethylene glycol
6000, 0.1 M citric acid pH 3.9, 0.15 M lithium sulfate monohydrate at 20°C. For
cryoprotection, crystals were briefly soaked in mother liquor solutions supplemented with
15% and subsequently with 30% ethylene glycol before flash cooling in liquid nitrogen.
3BNC60P61A Fab crystals grew in space group P21 (a = 64.6, b = 154.9, c = 74.2 Å; β =
109.7°) and were isomorphous to 3BNC60 Fab crystals (Scheid et al., 2011). Data were
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indexed, integrated and scaled using XDS (Kabsch, 2010). We used Phaser (McCoy et al.,
2007) to find a molecular replacement solution for two Fabs per asymmetric unit (chains A
and H and chains B and L for the heavy and light chains, respectively) using the 3BNC60
Fab structure (PDB code 3RPI) as a search model after omitting residues 59–66 of the heavy
chain. Residues 59–66 were built into Fo-Fc difference electron density maps after a few
rounds of iterative refinement including non-crystallographic symmetry restraints using
Phenix (Adams et al., 2010) and Coot (Emsley et al., 2010). The final 2.65 Å resolution
atomic model for two 3BNC60P61A Fabs (Rwork = 21.5%; Rfree = 25.6%) includes 12598
protein atoms (of which 6198 are hydrogen atoms), 199 water molecules, and 28 ligand
atoms (N-acetylglucosamine attached to Asn70 of the light chain) (Table S3). Using the
numbering established for the 3BNC60 Fab structure (Scheid et al., 2011), the residues
included in the final model are 1–132 and 141–217 of chain H, 2–132 and 141–217 of chain
A, 4–198 of chain L, and 4–199 of chain B. The first glutamine of the 3BNC60P61A heavy
chain was modeled as 5-pyrrolidone-2-carboxylic acid. 94.5%, 5.3% and 0.3% of the
residues were in the favored, allowed and disallowed regions of the Ramachandran plot,
respectively.
Thermal stability comparisons
Purified 3BNC60 and 3BNC60P61A Fabs were concentrated to 10 µM in 1 mM
dithiothreitol, 5 mM sodium chloride for CD studies. Far UV wavelength scans (200 nm to
250 nm) were recorded in 1 nm increments using an averaging time of 5 seconds on an Aviv
62A DS spectropolarimeter. Both spectra showed a distinct negative signal at 218 nm, thus
this wavelength was chosen for the thermal stability comparisons. Thermostability profiles
were obtained by monitoring the CD signal at 218 nm as the temperature was raised from
40°C to 95°C in 2°C increments, allowing 1 min of equilibration time after each temperature
step and averaging the CD signal over 30 sec of measurement. Transition midpoints (TmS)
were obtained by estimating the half-point of the ellipticity change between the native and
denatured states.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Framework mutations play a crucial role in broadly neutralizing HIV-1
antibodies
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Figure 1. Somatic mutations in the framework regions of HIV-1-reactive antibodies
(A) Ribbon representation of the variable domains of 3BNC60 (Scheid et al., 2011),
illustrating the CDRs (magenta) and the FWRs of the immunoglobulin heavy (blue) and
light (cyan) chain. (B) Illustration of Kabat and IMGT CDR (magenta) and FWR (IgH –
blue; IgL – cyan) assignments for the variable heavy and light chain domains of 3BNC60.
Gray arrows indicate β-strands defined by the crystal structure of the 3BNC60 Fab (Scheid
et al., 2011). (C) Position of FWR mutations in heavy and light chain of the 17 investigated
antibodies with broad neutralizing activity (see also Supplementary Data 1). Indicated are
silent (black) and replacement (red) mutations. Insertions are illustrated in blue. Number of
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replacement mutations within CDR1/2 and FWR1–4 are listed in the two columns at the
very right (see also Table S1). HIV-1 reactive antibodies with limited neutralization are
displayed in Figure S2.
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Figure 2. Binding and neutralization activity of mature and FWR-reverted (FWR-GL) broad
neutralizing antibodies
Evaluation of binding to gpl40YU2 ELISA (left) of mature antibodies (green) and antibodies
with FWRs reverted to germline (FWR-GL; blue, Supplementary Data 1B). Panels on the
right compare IC50 values for neutralization of Tier 1 (MW965.26, SF162.LS, Bal.26,
SS1196.1, DJ263.8, 6535.3) Tier 2 (RHPA4259.7, SC422661.8, TRO.11, YU2.DG), and
Tier 3 (PV0.4) viruses (Table S2). Only viruses are shown that were neutralized by the
mature version of the antibody. Neutralization activity is color-coded (blue arrow: < 0.001
µg/ml; dark red: IC50 between 0.001 and 0.01 µg/ml; red: > 0.01 – 0.1 µg/ml; orange: > 0.1 –
1 µg/ml; light orange: > 1 – 10 µg/ml; yellow: > 10 µg/ml; white: IC50 was not achieved up
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to the tested concentration). Antibodies (NIH45–46, 3BN60) with reverted CDR1/2 are
shown in Figure S2A and HIV-1 reactive antibodies with limited neutralization are
displayed in Figure S2B. The FWRs of VRC01, 3BNC60 and 3BNC131 were also reverted
according to IMGT (Giudicelli et al., 2006) and results are shown in Figure S2C. A detailed
illustration of the FWR mutations in 2G12 is shown in Figure S3.
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Figure 3. Binding and neutralization activity of mature and FWR-reverted (FWR-GL and FWR-
GLCR+) broad neutralizing antibodies
Evaluation of binding to gpl40YU2 ELISA (left) and SPR (middle) of mature antibodies
(green), antibodies with FWRs reverted to germline (FWR-GL, blue), and antibodies with
germline-reverted FWRs except gp120-contacting residues (FWR-GLCR+; light blue;
Supplementary Data ID). SPR results are shown for starting concentrations of 1 µM. BD
(below detection; no binding of the antibody was observed). Panels on the right compare
IC50 values for neutralization of Tier 1 to Tier 3 viruses (Table S2) as in Figure 2.
Neutralization activity is color-coded as indicated.
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Figure 4. Effects of a FWR insertion and a C” β-strand proline in clone RU01
Phylogenetic tree of the antibodies (Ig heavy chain) derived from the RU01 clone that
members include 3BNC117 and 3BNC60 (Scheid et al., 2011). Antibodies that carry both
the 4 amino acid insertion in FWR3 and the A61P somatic mutation are shown in red,
antibodies with only the A61P mutation are shown in orange, and antibodies without either
feature are shown in black. Bootstrap values (1000 trials, seed=111) of the phylogenetic tree
are indicated. Structure of 3BNC117 IGVH in its gpl20-bound conformation is shown in
Figure S5.
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Figure 5. Analysis of 3BNC60 insertion
(A) Superimposition of the structure of the VH domain of 3BNC60 (cyan) (Scheid et al.,
2011) onto the NIH45–46 VH domain from cocrystal structure of NIH45–46 (gray) bound to
gpl20 (gold) (Diskin et al., 2011) highlighting the 4 residue insertion in FWR3 of 3BNC60
(cyan arrow) and a potential interaction between the insertion and the gpl20 V1/V2 loop
(note that the V1/V2 loop was truncated in the gpl20 construct used for co-crystallization
with NIH45–46 and VRC01) (Diskin et al., 2011; Zhou et al., 2010). (B) Alignment of the
heavy chain FWR3 sequences of 3BNC60 (Scheid et al., 2011), 3BNC60 without the
3BNC60 insertion (3BNC60∆I), 3BNC55 (Scheid et al., 2011) and 3BNC55 containing the
3BNC60 insertion (3BNC55+I; Supplementary Data 1E). The 4 amino acid insertion in
FWR3 of 3BNC60 is shown in cyan and the region grafted into 3BNC60 from 3BNC55 in
order to delete the insertion without disrupting the structure is shown in gray. The amino
acid changes to introduce the insertion into 3BNC55 are shown in cyan. (C) In vitro
neutralization data (IC50 values in µg/ml) comparing the potencies of the antibodies. The
upper panel compares neutralization of selected viral strains by 3BNC60 and, 3BNC60∆I.
The lower panel compares the neutralization by a less potent member of the RU01 clone
(3BNC55), in which the FWR3 insertion of 3BNC60 was introduced (3BNC55+I). Reduced
and increased neutralization activity of the engineered antibodies (3BNC60∆I, 3BNC55+I)
is highlighted red and green, respectively. Neutralization data on VRC01 with and without
the 3BNC60 insertion is displayed in Table S2.
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Figure 6. Comparison of 3BNC60 and 3BNC60P61A structures, thermal denaturation profiles
and neutralizing activities
(A, left) 3BNC60P61A (magenta heavy, chain; yellow, light chain) was superimposed on the
structure of 3BNC60 (cyan, heavy chain; red, light chain; Table S3). The C” β-strand within
FWR3 of the VH domain differs in conformation between the two structures. (A, middle/
right) Close-up of the C’ and C” β-strands of 3BNC60P61A (magenta), 3BNC117 bound to
gol20 (yellow), 3BNC60 (cyan), and a murine Fab (green). The main chain atoms of the VH
domain C’ and C” β-strands of 3BNC60P61A exhibit a typical hydrogen bonding pattern for
an anti-parallel β-sheet. Three of the five inter-β-strand hydrogen bonds in 3BNC60P61A are
found in all three structures (yellow dashed lines), whereas 3BNC60 lacks two and the
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murine Fab/3BNC117 lacks one of the hydrogen bonds (green dashed lines in
3BNC60P61A). Co-crystallization of the 3BNC60-relative 3BNC117 with gpl20 shows that
Proline61 is accommodated without disrupting the C' - C" β-sheet when 3BNC117 is bound
to gpl20. Overview of the packing in crystals of 3BNC60 and 3BNC60P61A is shown in
Figure S6. (B) Thermal denaturation profiles of the 3BNC60 and 3BNC60P61A Fabs
monitored by the CD signal at 218 nm. TmS (indicated with arrows) were derived by
estimating the halfpoint of the ellipticity change between the beginning and end of each
transition. (C) In vitro neutralization data (IC50 values in µg/ml) comparing the 3BNC60 and
3BNC60P61A IgGs for a panel of 19 viruses. Reduced neutralization activity is highlighted
in red. Additional 9 viral strains (T250-4, T278-50, 620345.C01, X2088_c9, 89-Fl_2_25,
6540.v4.c1, CAP45.2.00.G3, 6545.v4.c1, Du422.1) were resistant to both 3BNC60 and
3BNC60P61A. The 3BNC60P61A mutant was not significantly more potent than 3BNC60
against any of the 27 strains tested.
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